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The gut-associated lymphoid tissues are the guardians of
the enteric immune system and integrate dietary and
microbial stimuli to maintain immunologic tolerance. How-
ever, during periods of persistent chronic inflammation,
such as in Crohn’s disease (CD), a dysfunctional lymphatic
system is a pathologic hallmark. Indeed, the predominant
histopathologic features of CD are lymphocytic lymphangi-
tis, occluded lymphatic vessels, and inflammatory granu-
lomas. These trademark features of chronic disease are
found in or around ectopic tertiary lymphoid tissues (TLT)
in the inflamed lamina propria (Gut 2008;57:1-4). In addi-
tion, the presence of TLT at the base of aphthous ulcers is
the earliest endoscopically evident lesion in CD and their
appearance heralds recurrent disease within the neo-
terminal ileum after ilectomy (Gut 1984;25:665-672). To
date, the function of intestinal TLT and their impact on the
etiology and pathogenesis of CD remains enigmatic, with
limited experimental evidence as to their role. How TLT
integrate into the pathophysiology of CD remains a critical
question, yet clinical investigation into their development
and function remains limited.
Randolph et al aimed to assess the integrity of mesen-
teric lymphatic vasculature in CD. First, they confirmed the
previous findings generated from immunopathologic
studies of intestinal mucosa, indicating defective lymphatic
function during active disease. To achieve this, patent blue
dye was injected into the serosa of ileal loops before sur-
gical resection, highlighting afferent lymphatic vessels
draining the lamina propria. This technique nicely
demonstrated a deviation of normal lymphatic vessels in
active CD, compared with non-CD counterparts and indi-
cated a remodeling of the vasculature in the mesentery.
Next, they used a 3-dimensional system to image whole
mount sections from a patient cohort undergoing ilectomyfor stricturing CD (to obtain cm3 tissue coverage).
Surprisingly, this work revealed advanced remodeling of
the lymphatic vascular tracks, with the presence of ectopic
lymphoid follicles within the collecting vessel line. A
border of adipocytes and no evident capsule, suggesting
that these organized structures were not sentinel lymph
nodes but TLT instead. The work by Randolph et al high-
lights that, although most studies have reported on
lymphatic capillaries in the intestinal wall, where collecting
vessels remove solutes and immune cells, the primary
functional site of lymphatic dysfunction may be the larger
vessels in the mesentery, which interface with sentinel
lymph nodes.
Comment. Our current understanding of the pathophysi-
ology of CD points toward a complex and heterogeneous
disease with an array of genetic and immunologic
defects. Yet, a consistent and primary pathologic hallmark
is the development of ectopic TLT and defective
lymphatic vasculature. However, our understanding of the
potential clinical significance of targeting lymphatics as a
therapeutic strategy in CD is limited, given the paucity
of preclinical and clinical studies investigating the biology of
lymphatics in the setting of inflammatory bowel disease.
A pressing need raised by Randolph et al is to generate
imaging techniques to investigate lymphatic function and
identify the presence of TLT within mesenteric lymphatics
of patients with CD, aiding in the assessment of clinical
course and treatment response. Although the appearance
of mesenteric TLT is a pathologic hallmark of treatment-
refractory fibrostenotic disease at ilectomy, it is not
known how and when they appear during the earlier
stages of CD, or whether they are responsive to thera-
peutic intervention. Equally important is to achieve an
understanding of the regional differences within the
intestine (ie, ileal versus colonic CD). Surprisingly, an
exhaustive pathologic characterization of TLT within the
mucosa and mesentery of patients with CD is still lacking,
hampering our ability to assess if the colon or ileum are
more permissive for lymphatic vessel dysfunction or TLT
development. The heterogeneous disease phenotypes and
clinical courses of inflammatory bowel disease will surely
have varying effects on regional lymphatic vessels and on
sentinel lymph node function. In preclinical mouse models,
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develop in response to inflammation and microbial
stimuli, dissipating with antiinflammatory interventions
(Gut 2013;62:53-62; J Immunol 2007;178:5659-5667).
Whether the mesenteric TLTs identified by Randolph et al
are regulated by the same immune cues or if they can be
modulated by therapeutics (eg, vedolizumab) is not
known.
The anatomic location of mesenteric TLT may give clues
as to their function. It is debatable whether mucosal TLT are
generated de novo within the chronically inflamed intestine
or whether they represent hyperplasia and maturation of
preexisting isolated lymphoid follicles. However, in the
setting of the observations made by Randolph et al, ectopic
TLT within afferent mesenteric lymphatics may either
highlight an attempt to restore lymph node function
(by generating new follicles and germinal centers) or
alternatively indicate sites of vessel damage where TLTs
form locally to contain disseminating microbes.
An intriguing question remains as to the function of
these ectopic follicles and whether they are contributing to
either a protective or pathologic immune environment. Are
TLT generating secretory immunoglobulin (Ig)A to “man the
border” following epithelial barrier defects and infiltration
of pathobiont bacteria (similar to isolated lymphoid folli-
cles)? Because IgA is not protective against invasive bacte-
ria, they may be generating antibacterial IgG in an attempt
to neutralize inflammation driven by invasive species. This
process has been previously observed in mouse models with
mesenteric fat-associated lymphoid clusters (Nat Immunol
2015;16:819-828) and in the setting of experimental colitis
on a background of failed antimicrobial immunity (RORgt-/-
mice; J Exp Med 2011;208:125-134). Although extensive
immunophenotyping of TLT was limited in this report,
dense clusters of B cells with defined germinal centers were
not observed by Randolph et al and CD20 immunopositive B
cells within TLT presented with a diffuse pattern. However,
TLT follicles were evident with segregated T-cell and B-cell
compartments and mature high endothelial venules
(as evidenced by PNAdþ vessels), indicating immune maturity.
This latest report by Randolph et al recognizes the lim-
itations of current mouse models, further supporting the
need for experimental models that recapitulate the histo-
pathologic features of CD. However, it is worth noting that
the authors may not be aware that the TNFDARE model has
transmural pathology restricted to the ileum, florid TLT in
mucosa, and marked induction of mesenteric fat-associated
lymphoid clusters (Gut 2013;62:53-62: Nat Immunol
2015;16:819-828). Whether TLT are present within
lymphatic vessels of the mesentery and contribute to vessel
occlusion and remodeling in this model is yet to be identi-
fied. Furthermore, the SAMP1YitFc and SAMP1 mouse
strains further develop ileal restricted TLT and the
appearance of “creeping fat” around the mesenteric vessels
(Inflamm Bowel Dis 2010;16:743-752). A global caveat to
using mouse models is that the lymphatic pump does not
function in a similar manner to higher vertebrates and
cannulating mouse mesenteric lymphatic vessels might not
be yet feasible technically (Ann N Y Acad Sci 2010;1207Suppl 1:E69-74). Thus, functionally assessing lymph flow in
relation to ileal inflammation and ectopic TLT may require
development of new murine (eg, rat) or primate models
of CD.
Is there a therapeutic window to repair damaged
afferent lymphatics and restore mucosal integrity during
CD? From a therapeutics perspective, recent elegant work
has demonstrated the efficacy of de novo lymphangio-
genesis as a viable intervention to ameliorate colonic
inflammation (J Clin Invest 2014;124:3863-3878). Danese
et al used an adenoviral system to overexpress vascular
endothelial growth factor-C, driving functional lymphatic
vessel generation in the intestine that attenuated pathol-
ogy in both dextran sodium sulfate–induced and IL-10-/-
colitis in mice. However, in light of the observations made
by Randolph et al in fibrostenotic stricturing CD, it remains
to be seen whether de novo generated lymphatic vessels
can really integrate with functional sentinel lymph nodes
in the mesentery to restore immune tolerance. Recent
work assessing the impact of infection with Yersinia
pseudotuberculosis demonstrated that infection induced
damage to afferent lymphatic vessels and resulted in
mesenteric bacterial leak, which persisted long after the
infection was cleared, in addition to developing fibrotic
mesenteric lymph nodes and compromised regional
immunity (Cell 2015;163:354-366). Thus, permeable
lymphatic vessels, fibrotic lymph nodes, and chylomicron
leak may represent a point of no return for tissue integrity
and function in CD.
A concern for the therapeutic dissociation of mesenteric
TLT with the intent of reversing the vascular remodeling
process is a potentially detrimental effect on regional
antimicrobial immunity. For example, lymphotoxin-b re-
ceptor signaling is a critical cytokine cue for the develop-
ment and organization of secondary lymphoid tissues and a
multitude of studies have used lymphotoxin-b receptor
blockade to disaggregate mature TLTs in various preclini-
cal models of infection and autoimmunity. However,
limited studies have reported on the subsequent impact on
posttreatment pathology. Although lymphotoxin-b receptor
inhibition will dissociate TLT in virtually all preclinical
models reported, it has dramatic effects on lymph node
structure and function including disruption of germinal
centers, high endothelial venule repression (Immunity
2005;23:539-550) and altered dendritic cell ratios (J
Immunol 2008;180:238-248). Although these experiments
serve as proof-of-principle studies, the site-directed de-
livery of therapeutics that target TLT structure and func-
tion in CD, with limited effects on antimicrobial immunity
may prove challenging. The report by Randolph et al em-
phasizes the need to investigate in detail the molecular
signatures and regional differences of TLT from patients
with inflammatory bowel disease, in an effort to identify
novel therapeutic targets. Building on this work and un-
derstanding how mesenteric TLT integrate into enteric
immunity (by controlling lymphocyte, dendritic cell, and
antigen trafficking patterns) is sure to advance our un-
derstanding of TLT function and their role in CD patho-
physiology. Given the marked lymphatic dysfunction in CD,
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EÓIN N. MCNAMEE
Mucosal Inflammation Program
School of Medicine
University of Colorado
Anschutz Medical Campus
Aurora, Colorado
JESUS RIVERA-NIEVES
Inflammatory Bowel Disease Center
Division of Gastroenterology
University of California San Diego and
San Diego VAMC
La Jolla, CaliforniaNeuroendocrine Tumors: A
Multidisciplinary Approach.
M. Pappotti and W.W. de Herder,
editors. 270 pp. $254.00. Basel,
Switzerland, Karger, 2015. ISBN:
978-3-318-02772-3. Web address
for ordering: www.karger.com.REVIEWER RATINGCoverage of relevant topics ++++Improvement over previously available media ++++Style of presentation and formatting ++++Quality of figures ++++Overall ++++Stars:
+: poor; ++: adequate; +++: fair; ++++: good; +++++: excellent.
The incidence of neuroendocrine tumors (NETs) has
increased multiple fold in the last 4 decades, providing more
impetus for clinicians to understand the heterogeneity of
NETs and to be able to recognize and treat these tumors
effectively. For this reason, the editors of this book sought to
provide a resource to those clinicians interested in this field.
In this book, a diverse group of authors provides a
multidisciplinary approach to the management of NETs, an
understudied group of tumors. This book addresses themore commonly encountered scenarios as well as unusual
challenges that may arise in the clinical course. The book is
comprehensive enough to serve as a reference book and
readily provides answers to those with specific questions
regarding NETs.
This book is a highly versatile book that would be useful
for generalists as well as NET specialists. It includes a diverse
array of topics including epidemiology, biomarkers, imaging,
and pathology. Even more important, it provides a
multidisciplinary approach to treatment, including
endoscopic, surgical, medical, and peptide receptor radionu-
clide therapy. For those seeking answers to specific questions,
the chapter titles clearly delineate the material covered in
each chapter, ensuring that material is easy to find. The depth
of coverage is complete and appropriate without over-
whelming the reader. The diversity of the authors’ specialties
highlights the multidisciplinary approach often needed with
these tumors, with perspectives written by gastroenterolo-
gists, endocrinologists, oncologists, and surgeons. The list of
authors reads as a worldwide “who’s who” of NET experts.
For gastroenterologists, the chapter on endoscopic ap-
proaches will prove particularly useful. Dermot O’Toole and
Laurent Palazzo provide several figures demonstrating ex-
amples of gastroenteropancreatic NETs; these include
endoscopic, endosonographic, and pathologic correlations.
They also effectively elucidate some of the most frequently
asked questions regarding gastric and duodenal NETs.
There are some limitations in this book. There is sig-
nificant overlap in the surgical chapters. For example, sur-
gical approaches for pancreatic NETs and metastatic disease
are covered in both the pancreatic surgery and gastroin-
testinal surgery chapters. There is also some variability in
the depth of coverage. The book does not include coverage
of surgical approaches in lung or thymic NETs. Certain
NETs, including ovarian and other rare tumors, are
excluded. It would have been helpful to have staging and
survival outcomes included. Although the staging classifi-
cation is alluded to within the pathology chapter, more
detail could have been provided in reference tables. Despite
these limitations, the book remains a necessary resource in
an understudied field.
Bottom Line: The book provides a practical review of
the diagnosis, management, and surveillance of this diverse
group of tumors. Although the focus of this book is clinical, it
also provides a glimpse of current translational work in the
field. Overall, the book is a much welcomed contribution to
the existing NET literature.
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